U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07404111) titled 'A Study of VV-14305 for the Treatment of Thyroid Eye Disease' on Oct. 24, 2025.
Brief Summary: The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease (TED)
Intervention:
GENETIC: VV-14305
VV-14305 will be administered via peribulbar injection.
OTHER: Sham (No Treatment)
Sham solution such as Saline
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kriya Therapeutics, Inc.
Disclaimer: Curated by HT Syndication....